Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Aclidinium/Formoterol FDC in COPD
NCT01049360Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2009
- Primary completion
- Aug 2010
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aclidinium bromide + formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Dec 2009; status: completed.
02
Drugs
aclidinium bromide + formoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01049360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01049360.